Dynavax Technologies Corporation (DVAX)

Market Cap	1.45B
Revenue (ttm)	236.15M
Net Income (ttm)	9.22M
Shares Out	130.89M
EPS (ttm)	0.06
PE Ratio	185.17
Forward PE	44.01
Dividend	n/a
Ex-Dividend Date	n/a

Volume	970,408
Open	11.29
Previous Close	11.28
Day's Range	11.00 - 11.29
52-Week Range	10.48 - 15.15
Beta	1.30
Analysts	Buy
Price Target	25.33 (+127.99%)
Earnings Date	May 8, 2024

About DVAX

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, In...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Feb 19, 2004
• Employees: 408
• Stock Exchange: NASDAQ
• Ticker Symbol: DVAX

Analyst Forecast

According to 3 analysts, the average rating for DVAX stock is "Buy." The 12-month stock price forecast is $25.33, which is an increase of 127.99% from the latest price.

Price Target

$25.33

(127.99% upside)

Analyst Consensus: Buy